Pharsight

Canasa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8217083 ABBVIE Mesalamine suppository
Jun, 2028

(3 years from now)

US8436051 ABBVIE Mesalamine suppository
Jun, 2028

(3 years from now)

Canasa is owned by Abbvie.

Canasa contains Mesalamine.

Canasa has a total of 2 drug patents out of which 0 drug patents have expired.

Canasa was authorised for market use on 05 November, 2004.

Canasa is available in suppository;rectal dosage forms.

The generics of Canasa are possible to be released after 06 June, 2028.

Drug Exclusivity Drug Exclusivity Expiration
M(M-187) Sep 02, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 05 November, 2004

Treatment: NA

Dosage: SUPPOSITORY;RECTAL

How can I launch a generic of CANASA before it's drug patent expiration?
More Information on Dosage

CANASA family patents

Family Patents